Adherence to isoniazid preventive therapy in Indonesian children: A quantitative and qualitative investigation

Merrin E Rutherford1, Rovina Ruslami, Winni Maharani

  • 1Centre for International Health, University of Otago, Dunedin, New Zealand. merrin.rutherford@gmail.com.

BMC Research Notes
|January 7, 2012
PubMed

Insights

Isoniazid preventive therapy (IPT) adherence is very low in Indonesian children under five, with cost and access being major barriers. Addressing these issues is crucial for reducing childhood tuberculosis.

Area of Science:

  • Public Health
  • Pediatric Infectious Diseases
  • Tuberculosis Control

Background:

  • Isoniazid preventive therapy (IPT) is recommended for child contacts of infectious tuberculosis cases.
  • Low reported adherence to IPT in children is a significant public health concern.
  • Risk factors for poor IPT adherence in pediatric populations remain largely uncharacterized.

Purpose of the Study:

  • To determine IPT adherence rates in children under five years old in an Indonesian lung clinic.
  • To identify risk factors associated with poor IPT adherence in this pediatric cohort.
  • To explore caregiver-reported barriers to IPT adherence through qualitative methods.

Main Methods:

  • Prospective study of children under five receiving IPT.
  • Logistic regression analysis to identify risk factors for adherence (defined as ≤3 months prescription collection).
  • In-depth interviews with caregivers of children with both good and poor adherence.

Main Results:

  • 74.4% of 82 eligible children exhibited poor IPT adherence.
  • High transport costs (OR 3.3) and medication costs (OR 20.0) were significantly associated with poor adherence.
  • Qualitative analysis revealed access, medication issues, health service experiences, and caregiver knowledge as key determinants.

Conclusions:

  • Childhood IPT adherence in this Indonesian setting is extremely low.
  • Financial, knowledge, health service, and medication-related barriers contribute to poor adherence.
  • Evidence-based interventions targeting these barriers are essential for effective childhood tuberculosis reduction.
Abstract

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...